Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1

A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)

Bambusa Therapeutics · NCT06944925

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–80 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 1
Target enrollment
286
US sites recruiting
2
Study start
May 8, 2025
Record last updated
July 1, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Randomized study of single and multiple doses of BBT002 in healthy volunteers and in adult patients with chronic obstructive pulmonary disease (COPD) or chronic rhinosinusitis with nasal polyps (CRSwNP).

Being studied: BBT002; Placebo

Conditions: Chronic Obstructive Pulmonary Disease

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria (Parts A, B, C, D, E, F, and G)

  • Age 18-65 years for HVs (Parts A, B, and E); age 35-80 years for patients with COPD (Parts C and F,); age 18-80 for patients with CRSwNP (Parts D and G)
  • Body mass index between 18.0-32.0 kg/m square, capped weight at 120kg, for HVs (Parts A, B, and E); body mass index between 16.0-35.0 kg/m square, capped weight at 125kg for patients (Parts C, D, F, and G)
  • Negative pregnancy tests for women of childbearing potential
  • Willingness to refrain from alcohol consumption for 24 hours prior to each study visit
  • Non-smokers, healthy current smokers (≤5 cigarettes/day), or ex-smokers
  • Adequate contraception use (for men and women of childbearing potential)
  • No clinically significant abnormalities or history of relevant diseases

Key Inclusion Criteria (Part C and F only) 1. Documented history of COPD with a post-bronchodilator Forced Expiratory Volume in 1 second/Forced Vital Capacity less than 0.70

Key Inclusion Criteria (Parts D and G)

  • Participants with confirmed diagnosis of CRSwNP

Key Exclusion Criteria for (Parts A, B, C, D, E, F, and G)

  • Positive viral serology for human immunodeficiency virus (HlV), hepatitis C virus (HCV), or hepatitis B (HBV)
  • Immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections
  • History of major metabolic, dermatological, liver, kidney, hematological or other significant disorders
  • Clinically relevant abnormal lab results, including low blood counts, liver enzymes, or abnormal kidney function
  • Positive drug/alcohol tests or abnormal vital signs at screening or Day -1
  • Abnormal Electrocardiogram(ECG) findings
  • History of drug/alcohol abuse in the past 2 years
  • History of severe allergic reactions or hypersensitivity

Key Exclusion Criteria (Part C and F only)

  • Current diagnosis of other significant pulmonary disease
  • Significant or unstable cardiovascular diseases
  • Recent clinically significant infection
  • Inability to perform spirometry

Key Exclusion Criteria (Parts D and G)

  • Steroid refractoriness: Refractory to systemic corticosteriods for CRSwNP
  • Sinonasal surgery (recent/extensiv)
  • Consitions interfering with nasal assessments
  • Excluded sinonasal/systemic diseases

Recruiting US locations

  • Equity Medical Bowling Green

    Bowling Green, KY 42104

    Site contact: Dr. James Allred · 844-378-9633 · Jallred@equity-med.com

  • Equity Medical LLC

    New York, NY 10023

    Site contact: Dr. Monalyn Zousias · 844-378-9633 · Mzouzias@equity-med.com

Study contacts (from the official record)

  • Tracy Ji · +86 18001322760 · Tracy.Ji@bambusatx.com
A Study of BBT002 in Healthy Volunteers (HVs) and in Adult… (NCT06944925) | Bored Studies